William T. McMillen

1.0k total citations
15 papers, 585 citations indexed

About

William T. McMillen is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, William T. McMillen has authored 15 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in William T. McMillen's work include TGF-β signaling in diseases (5 papers), Melanoma and MAPK Pathways (3 papers) and Bone Metabolism and Diseases (2 papers). William T. McMillen is often cited by papers focused on TGF-β signaling in diseases (5 papers), Melanoma and MAPK Pathways (3 papers) and Bone Metabolism and Diseases (2 papers). William T. McMillen collaborates with scholars based in United States and United Kingdom. William T. McMillen's co-authors include Jonathan M. Yingling, J. Scott Sawyer, Lei Yan, David K. Herron, Douglas W. Beight, Bryan D. Anderson, Robert M. Campbell, Stephen H. Parsons, Edward C. Smith and Faming Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer Research.

In The Last Decade

William T. McMillen

15 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William T. McMillen United States 9 412 212 95 57 50 15 585
Enrique Poradosu United States 10 308 0.7× 135 0.6× 86 0.9× 50 0.9× 39 0.8× 17 556
Douglas W. Beight United States 10 392 1.0× 210 1.0× 143 1.5× 42 0.7× 51 1.0× 15 616
Teresa Carrascal Spain 9 332 0.8× 190 0.9× 64 0.7× 20 0.4× 66 1.3× 9 587
Kevin J. Basile United States 10 434 1.1× 248 1.2× 28 0.3× 61 1.1× 76 1.5× 10 572
Rempei Yanagawa Japan 7 328 0.8× 180 0.8× 17 0.2× 84 1.5× 90 1.8× 8 537
Irene Filippi Italy 15 252 0.6× 102 0.5× 125 1.3× 26 0.5× 129 2.6× 29 618
Steven Do United States 7 293 0.7× 154 0.7× 49 0.5× 104 1.8× 37 0.7× 10 499
Rosemary Mayer‐Ezell United States 7 161 0.4× 191 0.9× 34 0.4× 39 0.7× 25 0.5× 8 395
Alain Laroze France 7 234 0.6× 79 0.4× 55 0.6× 21 0.4× 16 0.3× 11 400
Jennifer M. Shipman United States 11 378 0.9× 128 0.6× 95 1.0× 120 2.1× 123 2.5× 13 539

Countries citing papers authored by William T. McMillen

Since Specialization
Citations

This map shows the geographic impact of William T. McMillen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William T. McMillen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William T. McMillen more than expected).

Fields of papers citing papers by William T. McMillen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William T. McMillen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William T. McMillen. The network helps show where William T. McMillen may publish in the future.

Co-authorship network of co-authors of William T. McMillen

This figure shows the co-authorship network connecting the top 25 collaborators of William T. McMillen. A scholar is included among the top collaborators of William T. McMillen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William T. McMillen. William T. McMillen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Bhagwat, Shripad V., Weihua Shen, Baohui Zhao, et al.. (2020). Abstract 5225: Temporal inhibition of ERK is sufficient for tumor growth inhibition in KRAS-mutant or BRAF-mutant tumors. Cancer Research. 80(16_Supplement). 5225–5225. 2 indexed citations
2.
Pant, Shubham, Johanna C. Bendell, Ryan J. Sullivan, et al.. (2019). A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).. Journal of Clinical Oncology. 37(15_suppl). 3001–3001. 19 indexed citations
3.
Wu, Wenjuan, Shripad V. Bhagwat, Michelle L. Swearingen, et al.. (2018). Abstract LB-185: Combination of an ERK1/2 inhibitor (LY3214996) with VEGFR-2 inhibitor enhances anti-tumor activity in KRAS mutant non-small cell lung cancer. Cancer Research. 78(13_Supplement). LB–185. 1 indexed citations
4.
Dorsey, Frank C., Karim A. Benhadji, Lillian Sams, et al.. (2018). Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916. Cancer Research. 78(13_Supplement). 5245–5245. 13 indexed citations
5.
Wu, Wenjuan, Shripad V. Bhagwat, Constance King, et al.. (2017). Abstract 317: Combination of a novel ERK1/2 inhibitor (LY3214996) with CDK4 and CDK6 inhibitor (abemaciclib) enhances antitumor efficacy in KRAS mutant non-small cell lung cancer (NSCLC). Cancer Research. 77(13_Supplement). 317–317. 1 indexed citations
6.
7.
Kaneko, Takushi, et al.. (2007). Synthesis and antibacterial activity of C11, C12-cyclic urea analogues of ketolides. Bioorganic & Medicinal Chemistry Letters. 17(18). 5013–5018. 15 indexed citations
8.
Li, Hongyu, Yan Wang, William T. McMillen, et al.. (2007). A concise synthesis of quinazolinone TGF-β RI inhibitor through one-pot three-component Suzuki–Miyaura/etherification and imidate–amide rearrangement reactions. Tetrahedron. 63(47). 11763–11770. 15 indexed citations
9.
10.
Peng, Sheng-Bin, Lei Yan, Xiaoling Xia, et al.. (2005). Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal Transition. Biochemistry. 44(7). 2293–2304. 80 indexed citations
11.
Sawyer, J. Scott, Douglas W. Beight, Bryan D. Anderson, et al.. (2004). Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. Bioorganic & Medicinal Chemistry Letters. 14(13). 3581–3584. 141 indexed citations
12.
Yingling, Jonathan M., Robert B. Peery, J. Ott, et al.. (2004). 318 Dihydropyrrolopyrazoles as TGF-beta receptor kinase inhibitors for cancer therapy. European Journal of Cancer Supplements. 2(8). 97–97. 1 indexed citations
13.
Vieth, Michal, et al.. (2003). COMBINING MEDICINAL CHEMISTRY WITH CHEMOGENOMIC AND COMPUTER-AIDED STRUCTURE-BASED DESIGN IN DEVELOPMENT OF NOVEL KINASE INHIBITORS. Cellular & Molecular Biology Letters. 8. 3 indexed citations
14.
Sawyer, J. Scott, Bryan D. Anderson, Douglas W. Beight, et al.. (2003). Synthesis and Activity of New Aryl- and Heteroaryl-Substituted Pyrazole Inhibitors of the Transforming Growth Factor-β Type I Receptor Kinase Domain. Journal of Medicinal Chemistry. 46(19). 3953–3956. 197 indexed citations
15.
McMillen, William T., et al.. (1996). AN IMPROVED SYNTHESIS OF 2-(HYDROXYMETHYL)INDENE. Organic Preparations and Procedures International. 28(6). 702–704. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enrique Poradosu Breakdown of academic impact, for papers by Douglas W. Beight Breakdown of academic impact, for papers by Teresa Carrascal Breakdown of academic impact, for papers by Kevin J. Basile Breakdown of academic impact, for papers by Rempei Yanagawa Breakdown of academic impact, for papers by Irene Filippi Breakdown of academic impact, for papers by Steven Do Breakdown of academic impact, for papers by Rosemary Mayer‐Ezell Breakdown of academic impact, for papers by Alain Laroze Breakdown of academic impact, for papers by Jennifer M. Shipman
Rankless by CCL
2026